% | $
Quotes you view appear here for quick access.

Ariad Pharmaceuticals Inc. Message Board

bushiname 12 posts  |  Last Activity: Nov 12, 2015 1:41 PM Member since: May 17, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • With volume like today, the days to cover number has dropped significantly. It will only take 5 days like today to totally unwind all the short interests.

    Keep it up :-)

  • bushiname by bushiname Oct 22, 2015 10:58 AM Flag

    How many of you guys played this game before? MNKD trading reminds me of this game. How long can they keep this done and when will be the burst?

  • Reply to

    Piper Jaffray Drops Hammer on Mannkind

    by proulxra59 Sep 9, 2015 8:59 PM
    bushiname bushiname Sep 10, 2015 1:02 AM Flag

    I could not believe that either: earning lowered by 10% and price drop by 62.5%. I don't know whether to call this guy. ST-PID or desperate.

  • Reply to

    Doing Yeoman Work

    by prmco26 Sep 1, 2015 2:23 PM
    bushiname bushiname Sep 1, 2015 3:05 PM Flag

    Agree. "This is pretty good for not being bad." --Eeyore

    "RXs up in last report" Mind sharing on how one can get to the Rx numbers? Thanks.

  • bushiname bushiname Aug 31, 2015 1:39 PM Flag

    With longs like these, who needs shorts.

  • bushiname bushiname Aug 30, 2015 2:43 PM Flag

    They have a limited budget and they have choosen a path they believe to be less risky. They lost a lot in terms of "opportunity costs" because they missed the momentum which comes with FDA approval, with signing of partnership, with novelty of Afrezza.

    In other words, they missed the excitements and choosen the stead and boring, but perceived safer route.

  • If one put himself in SNY's shoes: if the ultimate goal is the success of Afrezza with a limited budget, what would one do?

    One approach do would be to tout Afrezza's advantages, garne as much excitements as one can, and hoping that the momentum generated will start the snowballing effect, blast over any obstacles on the way, and push Afrezza to be the starbuster it could be. This will be an exciting approach. We will know our success quickly. Drawback: if we run into an obstacle or cannot garner enough momentum before we run out of our budgeted time and money, Afrezza may fail before it reaches its full potential.

    The other approach would be a controlled roll out. Obstacles are anticipated, progress measured, improvements implemented, and better solutions worked out. As we go, we may even find enough positive feedbacks to justify spendings on marketing to garner interests. The drawbacks of this: we loss A LOT of momemum that was created natually by Afrezza's FSA approval, by the signing of partnership, and by excitements associated with novelty etc.

    I can understand why SNY has choosen the second approach given the fact Afrezza's closest comparable Exubera was not successful. I do not believe it to be the better choice. I would even argue that it is less likely to success because of the lost momentum and the lost free air time it would have gotten if we can attract the talking heads in the media. On the other hand, I do still think that Afrezza will scuccess and we longs just have to suck it up and endure though.

    It is unfortunate that the short sellers decided to target Afrezza. But what can we longs do other than being steadfast, knowing that they cannot keep the good men down?

  • bushiname by bushiname Aug 30, 2015 1:55 PM Flag

    For whatever it is worth: Afrezza is in the latest issue for this week. This time, the ad featured an attractive lady. Not the steriotype, perfect bodied athelete model lady. Just an ordinary looking but attrative lady. There was no ad in the issue last week, though. So, so far, the ad is in every other week.

  • Reply to

    Some major options action going on today

    by mnholdem Aug 28, 2015 2:34 PM
    bushiname bushiname Aug 28, 2015 3:05 PM Flag

    Why are they very different? Buying calls are bullish. Selling covered calls is a hedge on a long position, which is still bullish. The hedge makes the position safer as it: If the stock goes down, one does not loss money or does not loss as much money. The trade off is the position no longer benefit if the stock goes above the strike price.

  • Reply to

    Interesting read. The Endo's are talking.

    by pkgossett Aug 27, 2015 1:34 PM
    bushiname bushiname Aug 27, 2015 3:32 PM Flag


    In the long run, the stock market is a weighing machine. MNKD will be heavy as Afrezza improves people's life.

    BTW, does anybody know why the study does not name Afrezza directly and write the article using generic terms such as "prandial inhaled insulin ", of which Afrezza is the only choice?

    Also, wonder if the 176 patients got counted in the script count. If not, when their scripts start to be counted, Should we expect to see a big jump in script count?

  • Reply to

    medical question

    by nanospeak Aug 26, 2015 1:28 PM
    bushiname bushiname Aug 26, 2015 2:01 PM Flag

    Layman's terms, the only ones I understand: Your body is insensitive so it does not know when to produce insulin.

    Here comes you brain: you know you are going to need it soon (like before a hearty meal) so you take some.

    Simple, right?

  • I endured a couple of sharp drops in the market before but this felt a little different. It almost felt that this one one is man made. In other words, could this, that the whole market goes down, actually be caused by short sellers? Just wondering if that is possible and if so, what would be the indications?

6.35-0.14(-2.16%)Nov 24 3:59 PMEST